NextCure Stock Price - NXTC

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 49.90 ▼ -0.22 (-0.44%)
Company Name Stock Ticker Symbol Market Type
NextCure Inc NXTC NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -2.78 -5.26% 50.12 53.70 49.90 53.32 52.90 23:59:42
Bid Price Ask Price Spread Spread % News
36.05 61.00 24.95 40.9% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,475 231,263 $ 51.37 $ 11,879,942 349,907 13.86 - 109.00
Last Trade Time Type Quantity Stock Price Currency
17:22:25 formt 178 $ 49.90 USD

NextCure Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 1.38B 27.44M -2.27 - 26.85M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

NextCure News

Loading Messages....

Latest NXTC Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NXTC Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week58.5558.7747.7553.46288,401-8.43-14.4%
1 Month55.0670.9847.7557.40368,909-4.94-8.97%
3 Months25.73109.0023.6858.93614,52524.3994.79%
6 Months16.17109.0016.0454.58322,20533.95209.96%
1 Year15.55109.0013.8651.29262,49834.57222.32%
3 Years15.55109.0013.8651.29262,49834.57222.32%
5 Years15.55109.0013.8651.29262,49834.57222.32%

NextCure Description

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.